| Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes |
|
Clinical Lymphoma, Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
| Early transfusion patterns improve the Molecular International Prognostic Scoring System (IPSS-M) prediction in myelodysplastic syndromes |
|
Journal of Internal Medicine |
Myelodysplastic Syndromes (MDS) |
| Alternative donor transplantation for severe aplastic anemia: a comparative study of the SAAWP EBMT |
|
Blood |
Aplastic Anemia |
| Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia |
|
Haematologica |
Aplastic Anemia |
| Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities |
|
Current Hematologic Malignancy Reports |
Myelodysplastic Syndromes (MDS) |
| Hemolysis events in the Phase 3 PEGASUS study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria |
|
Blood Advances |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Quality of life after immune suppressive therapy in aplastic anemia |
|
Annals of Hematology |
Aplastic Anemia |
| T-cell dysfunctions in myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study |
|
Advances in Therapy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies |
|
Expert Opinion on Biological Therapy |
Myelodysplastic Syndromes (MDS) |
